Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $19.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
